Ranitidine products recalled because of a nitrosamine impurity
What the notice records
| Product | Over-the-counter and prescription ranitidine drugs (LATEST UPDATE: March 11, 2022 – Pharmascience Inc. recall) |
|---|---|
| Issue | Product safety |
| What you should do | Talk to your doctor or pharmacist at your earliest convenience about alternative, non-ranitidine treatment options appropriate for your health circumstances. There are many prescription and over-the-counter drug alternatives in Canada that are authorized for the same or similar uses as ranitidine.Individuals taking a prescription ranitidine drug, including a recalled product, should not stop taking it unless they have spoken to their health care provider and obtained alternative treatment, as the risk of not treating the condition may be greater than the risk related to NDMA exposure.Contact your health care provider if you have taken a ranitidine product and you have concerns about your health.Report any health product adverse events or complaints to Health Canada.Canadians with questions about the recalls can contactApotex Inc. via Stericycle Inc. at 1-877-574-5043;Dominion Pharmacal at 1-888-550-6060, or by e-mail at [email protected];Laboratoire Riva Inc. at 1-450-434-7482, or by e-mail at [email protected];Pro Doc Limitée at 1-800-361-8559, or by e-mail at [email protected];Ranbaxy Pharmaceuticals Canada Inc. at 1-866-840-1340, or by e-mail at [email protected] Canada at 1-800-361-3062;Sanis Health Inc. at 1-866-236-4076;Sanofi Consumer Health Inc. at 1-800-636-3664 or by email at [email protected];Sivem Pharmaceuticals ULC at 1-855-757-4836;Pharmascience Inc. at 1-888-550-6060, or by email at [email protected];Teva Canada Limited at 1-800-268-4129;Vita Health Products Inc. at 1-877-637-7557.Related links:Health Canada assessing NDMA in ranitidine (2019-09-13)Apotex Inc. ranitidine recall (2019-09-24)Sanofi Consumer Health Inc. Zantac recall (2019-10-18)Pharmascience Inc. ranitidine recall (2019-10-25)Vita Health Products Inc. ranitidine recall (2019-10-25)Health Canada updates Canadians on its ongoing assessment of nitrosamine impurities in certain drugs (2019-12-02)Status of ranitidine drugs in Canada (2020-07-23) |
| Category | Health products |
| Publishing body | Communications and Public Affairs Branch |
| Class | Class not stated |
| Last updated | 2022-03-11 |
Read the official notice on recalls-rappels.canada.ca
Everything in Health products · Everything from Communications and Public Affairs Branch
Read this correctly
This page reproduces the fields published on the notice and links to the notice itself. It is not a rating and not a statement about a product's current condition, availability or safety.
This notice carries no class in the published data. A blank class means the field is blank — it is not a statement that the product was low risk.
Privacy
This site publishes records that governments already publish. It sets no cookie and makes no request to Google unless you accept one. Read more below.
About this record
Every recall notice published by Health Canada: the product, the issue recorded against it, the class assigned, and the official notice itself. A record of what was published, on the date it was published.
Source: Health Canada — Recalls and safety alerts (open data) — Open Government Licence – Canada. Data refreshes daily. Every page links the row it came from.
What this site is not. It is a copy of an official record. It is not a judgement about any business, building or person, and it is not advice. If the record is wrong, the source above is where it is corrected.